Clinical Trials in San Francisco

Showing 1761-1780 of 6,211 trials

Development of a Health-Related Symptom Index for Participants With and Either Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions

NCT04276935

This trial develops a health-related symptom index for participants with and either treated or monitored for anal high-grade squamous intraepithelial lesions. The health-related quality of life index may help to capture the symptoms and related experiences of living with or being treated for high-grade squamous intraepithelial lesions.

High Grade Anal Canal Squamous Intraepithelial NeoplasiaHuman Immunodeficiency Virus

AIDS Malignancy Consortium20 participantsStarted Nov 2018

San Francisco, California, United States • Miami, Florida, United States • Chicago, Illinois, United States +1 more locations

TERMINATEDPhase 2< 1 mile

A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.

NCT04840199

This was an open-label, controlled study, conducted at US sites to evaluate the anti-inflammatory effectiveness of the study drug letermovir in adults with HIV and asymptomatic cytomegalovirus (CMV) who were on antiretroviral therapy (ART)-mediated suppression. Participants were randomly assigned to receive either letermovir once daily or no anti-CMV treatment, for 48 weeks. The primary hypothesis of this study was that letermovir would cause a greater reduction in plasma soluble receptor for tumor necrosis factor type II (sTNFRII) levels than no anti-CMV treatment at weeks 46/48.

HIV InfectionsCytomegalovirusCMV

National Institute of Allergy and Infectious Diseases (NIAID)44 participantsStarted Apr 2022

San Diego, California, United States • San Francisco, California, United States • Aurora, Colorado, United States +12 more locations

Development of a Health-Related Symptom Index for Participants With and Either Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions

A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.

Find Trials by Condition in San Francisco

Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

Research on Equity in Abortion Care by TeleHealth

Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome

Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination

Evaluation of Conventional Ablation With or Without Focal Impulse and Rotor Modulation to Eliminate Human AF

CoolSculpting and RF for the Submental

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)

Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)

XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer

TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer

Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours

Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria

A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer

Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC)

MGD019 DART® Protein in Unresectable/Metastatic Cancer

EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC